Amine derivative compounds for treating ophthalmic diseases...

Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S649000

Reexamination Certificate

active

08076516

ABSTRACT:
Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

REFERENCES:
patent: 3911151 (1975-10-01), Yokoyama et al.
patent: 5227372 (1993-07-01), Folkman
patent: 2002/0058685 (2002-09-01), Hamilton
patent: 2003/0032078 (2003-02-01), Travis
patent: 2003/0186981 (2003-10-01), Hamilton et al.
patent: 2004/0186061 (2004-09-01), Meese et al.
patent: 2006/0069078 (2006-03-01), Rando
patent: 2006/0069110 (2006-03-01), Andersen et al.
patent: 2006/0116373 (2006-06-01), Dollinger et al.
patent: 2006/0211694 (2006-09-01), Devadas
patent: 2006/0252107 (2006-11-01), Kubota et al.
patent: 2006/0281812 (2006-12-01), Slatter et al.
patent: 2006/0281821 (2006-12-01), Palczewski et al.
patent: 2007/0072920 (2007-03-01), Hellberg et al.
patent: 2007/0149480 (2007-06-01), Ghosh et al.
patent: WO 03/059872 (2003-07-01), None
patent: WO 2004/030671 (2004-04-01), None
patent: WO 2005/105760 (2005-11-01), None
patent: WO 2008/011560 (2008-01-01), None
patent: WO 2008/021388 (2008-02-01), None
patent: WO 2008/131368 (2008-04-01), None
patent: WO 2008/077057 (2008-06-01), None
patent: WO 2008/005794 (2009-08-01), None
Rangisetty et. al., “1-[2-Methocy-5-(3-phenylpropyl]-2-aminopropane unexpectedly shows 5-HT2A Serotonin Receptor Affinity and Antagonist Character”, J. Med. Chem. 2001, 44, pp. 3283-3291.
Tavora de Albuquerque Silva, A. et al., Mini Reviews in Medicinal Chemistry, vol. 5, 2005, 893-914.
Zanon-Moreno, V. et al., Molecular Vision, vol. 14, 2008, 2143-47.
GB0819399.7 Search Report dated Apr. 1, 2009.
Golczak et al., “Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle,” PNAS 102(23):8162-8167 (2005).
Maeda et al., “Evaluation of the role of the retinol G protein-coupled receptor (RGR) in the vertebrate retina in vivo,” J. Neurochem. 85(4):944-956 (2003).
Mata et al., “Isomerization and Oxidation of Vitamin A in Cone-Dominant Retinas: A Novel Pathway for Visual-Pigment Regeneration in Daylight,” Neuron 36:69-80 (2002).
Minami et al., “Enzymatic Approach to Unnatural Glycosides with Diverse Aglycon Scaffolds Using Glycosyltransferase VinC,” JACS 127:6148-6149 (2005).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Amine derivative compounds for treating ophthalmic diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amine derivative compounds for treating ophthalmic diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine derivative compounds for treating ophthalmic diseases... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4297360

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.